drugset / Trial / NCT06012448

The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction

NCT06012448

NaSingle-groupOpen-labelTreatment

Summary

This research is studying a drug called dupilumab to learn about its safety and its effect as a treatment for participants with dermal hypersensitivity reaction. This study will help better understand why and how dermal hypersensitivity reaction occurs and how dupilumab might help treat this condition.

Timeline

Start
2023-10-02
Primary completion
2025-01-07
Completion
2025-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Dupilumab Monoclonal antibody 300 mg Subcutaneous